Last reviewed · How we verify
ages 12-17
ages 12-17 is a Small molecule drug developed by Pfizer. It is currently FDA-approved.
Here's a 2-sentence factual summary of ages 12-17 based on the provided facts: Children and adolescents aged 12-17 are not directly mentioned in the ClinicalTrials.gov facts, but the study "EndeavorOTC Research Study in College Students" suggests that EndeavorOTC may be used for cognitive improvement in university students, which implies potential benefits for younger students as well. However, there is no direct evidence from ClinicalTrials.gov to support the use of EndeavorOTC in children and adolescents aged 12-17, and further research is needed to establish its efficacy and safety in this age group.
At a glance
| Generic name | ages 12-17 |
|---|---|
| Sponsor | Pfizer |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity (PHASE2)
- A Phase 2 Randomized Multisite Trial to Inform Public Health Strategies Involving the Use of MVA-BN Vaccine for Mpox (PHASE2)
- A Longitudinal Investigation of the Endocrine and Neurobiologic Events Accompanying Puberty
- A Clinical Trial Via Telepsychiatry of Treatments for the Management of Emotional Dysregulation in Youth (PHASE4)
- Early Initiation of Oral Therapy With Cyclosporine and Eltrombopag for Treatment Naive Severe Aplastic Anemia (SAA) (PHASE2)
- Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) (PHASE3)
- General Population Level Estimation for Type 1 Diabetes Risk in Children During Routine Care Delivery
- Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ages 12-17 CI brief — competitive landscape report
- ages 12-17 updates RSS · CI watch RSS
- Pfizer portfolio CI
Frequently asked questions about ages 12-17
What is ages 12-17?
Who makes ages 12-17?
What development phase is ages 12-17 in?
Related
- Manufacturer: Pfizer — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing